Evidence map›Paper›PMID 39896719›Full record

ArticleLeukemia research reports2025

Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas.

Gen Hasegawa, Noriharu Nakagawa, Yoshimichi Ueda, Masahide Yamazaki

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Emerging therapeutic strategies for CD30-positive lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gen HasegawaDepartment of Hematology, Keiju Medical Center, Nanao, Ishikawa, Japan.
Noriharu NakagawaDepartment of Hematology, Keiju Medical Center, Nanao, Ishikawa, Japan.
Yoshimichi UedaDepartment of Pathology, Keiju Medical Center, Nanao, Ishikawa, Japan.
Masahide YamazakiDepartment of Hematology, Keiju Medical Center, Nanao, Ishikawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brentuximab vedotin (BV) has demonstrated efficacy against CD30

Indexed as

Brentuximab vedotinDifferent phenotypePeripheral T-cell lymphomaRetreatment

Identifiers

PMID39896719
PMCPMC11786849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.